Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
about
Mutational profiling of kinases in glioblastoma.Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentBiomarkers for determining the prognosis in chronic myelogenous leukemiaImatinib in chronic myeloid leukemia: an overviewClinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsTyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementChanging the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EUCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trA phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasBosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Selecting the best frontline treatment in chronic myeloid leukemiaTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaAutomated synthesis and visualization of a chemotherapy treatment regimen network.Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceTyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Practice gaps and barriers to optimal care of hematologic malignancies in the United States.The choice of first-line chronic myelogenous leukemia treatment.Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsIn vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsPonatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisThe Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaBest Practices in Chronic Myeloid Leukemia Monitoring and ManagementEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
P2860
Q21261249-517A42BE-9B83-4847-BF64-9AEB5553E000Q24607114-3FC69307-146E-4B9C-BE26-469C9272B819Q26738514-94D4DCDA-5986-4466-BB19-25AC2B36C9B0Q26749324-1D66CB4F-1C97-4781-AD4D-9BFB0AE88193Q26766299-D7F805D0-84FA-4F40-95B8-801CDBB6EA68Q26824660-B80D395E-0938-4766-9736-BBDAD7FB6774Q26865086-E83C9E86-7DA5-4066-B661-B9A80FEAC9FCQ27004032-B0D25633-3188-45E5-8A4F-67CFFE787743Q28075963-F8E865DF-6FDD-473E-9202-DADE44BB7B1CQ28086893-092224D3-D78D-4094-BE3D-AA2C3269E8F4Q28484913-C57805C6-DD5D-46A8-B9B5-21FF3EF1F9A8Q30242015-BFF89DE0-2D31-4274-B2AD-EAC8C84F5C2CQ30891587-FCA027D9-6840-4052-8718-829C26C02F99Q31033077-ED7D7E0A-E081-4ADB-A70A-5554A5E49C02Q33411250-F504B395-8816-450C-8D00-70E89B8F5E9FQ33412495-553A9264-968F-49A9-AEAD-5FF6495467DFQ33414487-F9C4D2EF-CABB-41E7-8112-FC073AB1E9C2Q33442587-5F33EAF9-0C14-4BD1-B5F8-EF268B4D3DABQ33602552-1E59BB28-103B-4F54-A5A1-7BD37DA90A81Q33764253-16E0AFA5-6E97-4043-9083-5A874227F6F6Q33806617-8419C5B1-13DE-43B2-90FE-35874E68AA5AQ33822231-92A58D1B-E0C8-437E-ACEB-B218B5FF2985Q34022125-EA62E038-F6A1-46C7-A971-0B90F8A8E9EBQ34272962-1128E547-F33B-4B54-A46F-4A862E801B9EQ34658293-C8C6E39F-3707-4E3B-A298-DCC783401A4AQ34763374-BE950E06-7C2D-4500-A35F-36D10B042419Q35008618-4FF9929D-CE26-47C6-AB63-CE3DB76E4A2EQ35070978-37D44BBC-4736-4ACE-972F-BC13B5F8897CQ35194464-208EDF83-3994-4B46-A627-54C0AEEE4A0CQ35207616-A19DCD55-4A90-4E7D-9F9C-36F244D10B60Q35221071-F0783229-DD2C-4B75-9476-B2486F1FAA29Q35743878-C7787FD2-2DF4-4F69-9E54-894BA4FB4BDEQ35819214-839BF6E1-D093-4E10-AA88-14EDC54A3B77Q35873909-309FA078-1592-473D-812A-3790199BB9D7Q36104098-4A8E36B0-1C50-494C-9A40-588978264552Q36316309-5026A191-DCF7-420C-8CAA-0E46124A5CD5Q36400944-463162A0-877F-42E5-99BE-B99EEB6F42BBQ36547224-F3EA0B9F-4225-4DBD-90E2-6BAFFFD1C676Q36884361-3A0247B5-89A5-4194-96E6-684311F01AD6Q37026032-D8B754A0-C37B-4DC9-9EF4-4346ABC00954
P2860
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@ast
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@en
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@nl
type
label
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@ast
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@en
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@nl
prefLabel
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@ast
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@en
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@nl
P2093
P2860
P50
P921
P356
P1476
Bosutinib versus imatinib in n ...... : results from the BELA trial.
@en
P2093
Athena M Countouriotis
Christine Powell
Dong-Wook Kim
Hemant Malhotra
Irina Dyagil
Karïn Gogat
Laimonas Griskevicius
Tim H Brümmendorf
P2860
P304
P356
10.1200/JCO.2011.38.7522
P407
P577
2012-09-04T00:00:00Z